Complete financial analysis of Novo Nordisk A/S (NVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novo Nordisk A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- IAC InterActive Corp. (IAC) Income Statement Analysis – Financial Results
- Contact Gold Corp. (C.V) Income Statement Analysis – Financial Results
- BAHADIR KIMYA (BAHKM.IS) Income Statement Analysis – Financial Results
- KING Co., Ltd. (8118.T) Income Statement Analysis – Financial Results
- Fujian SBS Zipper Science&Technology Co., Ltd (002098.SZ) Income Statement Analysis – Financial Results
Novo Nordisk A/S (NVO)
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.26B | 176.95B | 140.80B | 126.95B | 122.02B | 111.83B | 111.70B | 111.78B | 107.93B | 88.81B | 83.57B | 78.03B | 66.35B | 60.78B | 51.08B | 45.67B | 41.89B | 38.75B | 33.71B | 29.23B | 26.61B | 25.15B | 23.72B | 20.82B | 20.94B | 17.91B | 16.98B | 14.90B | 13.71B | 13.52B | 13.15B | 10.67B | 9.83B | 8.33B | 7.62B | 5.63B | 5.03B | 4.19B | 4.16B |
| Cost of Revenue | 35.77B | 28.45B | 23.66B | 20.93B | 20.09B | 17.62B | 17.63B | 17.18B | 16.19B | 14.56B | 14.14B | 13.47B | 12.59B | 11.68B | 10.44B | 10.13B | 9.80B | 9.59B | 9.17B | 8.11B | 7.46B | 6.62B | 5.96B | 4.38B | 5.05B | 4.39B | 4.72B | 4.17B | 3.83B | 3.83B | 6.41B | 2.53B | 4.80B | 4.13B | 3.76B | 2.72B | 2.59B | 3.29B | 2.07B |
| Gross Profit | 196.50B | 148.51B | 117.14B | 106.01B | 101.93B | 94.21B | 94.06B | 94.60B | 91.74B | 74.24B | 69.43B | 64.56B | 53.76B | 49.10B | 40.64B | 35.53B | 32.09B | 29.16B | 24.55B | 21.13B | 19.15B | 18.53B | 17.75B | 16.44B | 15.89B | 13.52B | 12.26B | 10.74B | 9.88B | 9.68B | 6.74B | 8.14B | 5.03B | 4.21B | 3.85B | 2.91B | 2.44B | 893.58M | 2.09B |
| Gross Profit Ratio | 84.60% | 83.92% | 83.20% | 83.51% | 83.54% | 84.25% | 84.21% | 84.63% | 85.00% | 83.60% | 83.08% | 82.74% | 81.03% | 80.78% | 79.56% | 77.81% | 76.60% | 75.26% | 72.81% | 72.27% | 71.96% | 73.66% | 74.85% | 78.96% | 75.89% | 75.50% | 72.20% | 72.04% | 72.07% | 71.64% | 51.26% | 76.32% | 51.22% | 50.49% | 50.59% | 51.75% | 48.49% | 21.34% | 50.14% |
| Research & Development | 32.44B | 24.05B | 17.77B | 15.46B | 14.22B | 14.81B | 14.01B | 14.56B | 13.61B | 13.76B | 11.73B | 10.90B | 9.63B | 9.60B | 7.86B | 7.87B | 8.55B | 6.32B | 5.07B | 4.38B | 4.20B | 4.13B | 3.96B | 3.22B | 3.36B | 3.40B | 2.77B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.86B | 4.47B | 4.05B | 3.96B | 4.01B | 3.92B | 3.78B | 3.96B | 3.86B | 3.54B | 3.51B | 3.31B | 3.25B | 3.72B | 2.76B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 56.74B | 46.22B | 37.01B | 32.93B | 31.82B | 29.40B | 28.34B | 28.38B | 28.31B | 23.22B | 23.38B | 21.54B | 19.00B | 18.20B | 15.42B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.60B | 50.68B | 41.06B | 36.89B | 35.83B | 33.31B | 32.12B | 32.34B | 32.17B | 26.76B | 26.89B | 24.86B | 22.25B | 21.92B | 18.18B | 15.82B | 14.90B | 14.00B | 11.79B | 10.30B | 9.67B | 9.42B | 9.06B | 7.93B | 7.50B | 6.59B | 6.02B | 7.69B | 6.87B | 6.79B | 3.99B | 6.29B | 3.04B | 2.63B | 2.33B | 1.65B | 1.52B | 0.00 | 1.15B |
| Other Expenses | -119.00M | -1.03B | -332.00M | -460.00M | -600.00M | -1.15B | -1.04B | -737.00M | -3.48B | -770.00M | -682.00M | -666.00M | 0.00 | 0.00 | 0.00 | -572.36M | -322.18M | -271.23M | -397.15M | -581.71M | -1.12B | -997.95M | -860.46M | 1.03B | 1.43B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| Operating Expenses | 93.92B | 73.70B | 58.50B | 51.89B | 49.45B | 46.97B | 45.10B | 46.17B | 42.30B | 39.75B | 37.94B | 35.09B | 31.88B | 31.52B | 26.05B | 23.12B | 23.13B | 20.04B | 16.47B | 14.10B | 12.75B | 12.56B | 12.16B | 12.19B | 12.28B | 11.46B | 9.93B | 8.76B | 8.01B | 7.84B | 4.79B | 6.99B | 3.63B | 3.15B | 2.80B | 1.98B | 1.79B | 224.68M | 1.35B |
| Cost & Expenses | 129.69B | 102.15B | 82.16B | 72.82B | 69.54B | 64.58B | 62.73B | 63.35B | 58.48B | 54.31B | 52.08B | 48.55B | 44.47B | 43.20B | 36.49B | 33.26B | 32.93B | 29.63B | 25.64B | 22.20B | 20.22B | 19.18B | 18.12B | 16.57B | 17.33B | 15.84B | 14.65B | 12.92B | 11.84B | 11.68B | 11.20B | 9.51B | 8.43B | 7.28B | 6.57B | 4.69B | 4.38B | 3.52B | 3.43B |
| Interest Income | 1.07B | 239.00M | 2.89B | 337.00M | 65.00M | 51.00M | 69.00M | 52.00M | 85.00M | 167.00M | 56.00M | 125.00M | 514.00M | 382.00M | 375.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 739.00M | 378.00M | 2.45B | 390.00M | 220.00M | 85.00M | 90.00M | 65.00M | 6.05B | 563.00M | 55.00M | 1.79B | 959.00M | 2.06B | 1.27B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.41B | 6.60B | 5.31B | 5.28B | 4.68B | 3.81B | 2.87B | 2.65B | 3.04B | 3.60B | 3.57B | 2.82B | 20.00M | 2.85B | 3.27B | 2.08B | 1.90B | 1.64B | 1.21B | 1.44B | 1.63B | 1.33B | 208.85M | 665.76M | 1.19B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| EBITDA | 113.33B | 76.41B | 64.83B | 58.57B | 56.31B | 51.57B | 51.69B | 50.58B | 49.58B | 38.09B | 35.25B | 30.44B | 24.94B | 21.25B | 17.80B | 14.48B | 11.97B | 10.76B | 9.29B | 8.47B | 8.02B | 6.05B | 5.81B | 4.91B | 4.81B | 2.09B | 2.31B | 2.15B | 2.61B | 2.42B | 2.26B | 812.29M | 1.54B | 1.19B | 1.27B | 1.02B | 708.41M | 675.51M | 673.20M |
| EBITDA Ratio | 48.79% | 46.36% | 47.98% | 47.43% | 47.36% | 45.75% | 46.70% | 46.18% | 48.63% | 42.90% | 41.95% | 41.39% | 33.75% | 35.77% | 35.63% | 31.71% | 25.91% | 27.76% | 27.54% | 28.98% | 22.57% | 24.06% | 24.48% | 23.58% | 22.94% | 11.68% | 13.59% | 14.45% | 19.05% | 17.91% | 17.22% | 7.61% | 15.70% | 14.23% | 16.61% | 18.05% | 14.09% | 16.13% | 16.19% |
| Operating Income | 102.57B | 74.81B | 58.64B | 54.13B | 52.48B | 47.25B | 48.97B | 48.43B | 49.44B | 34.49B | 31.49B | 29.47B | 22.37B | 18.89B | 14.93B | 12.40B | 8.95B | 9.12B | 8.08B | 7.03B | 4.38B | 4.72B | 5.60B | 4.24B | 3.62B | 623.53M | 1.17B | 1.09B | 1.47B | 1.37B | 1.47B | 118.55M | 950.89M | 664.82M | 793.56M | 692.21M | 442.00M | 450.83M | 473.30M |
| Operating Income Ratio | 44.16% | 42.28% | 41.65% | 42.64% | 43.01% | 42.25% | 43.84% | 43.33% | 45.81% | 38.84% | 37.68% | 37.77% | 33.72% | 31.08% | 29.24% | 27.16% | 21.38% | 23.53% | 23.95% | 24.05% | 16.46% | 18.77% | 23.60% | 20.39% | 17.26% | 3.48% | 6.86% | 7.29% | 10.74% | 10.10% | 11.14% | 1.11% | 9.67% | 7.98% | 10.42% | 12.30% | 8.79% | 10.77% | 11.38% |
| Total Other Income/Expenses | 2.10B | -5.75B | 436.00M | -996.00M | -3.93B | 367.00M | -287.00M | -634.00M | -5.96B | -396.00M | 1.05B | -1.66B | -449.00M | -605.00M | -945.00M | 320.95M | 2.03B | 45.20M | 144.99M | 477.44M | 1.18B | 1.57B | 417.70M | 601.59M | 340.08M | 3.12B | 2.01B | 1.44B | 681.11M | 565.52M | 407.02M | 1.55B | 511.52M | 473.05M | 255.71M | 213.09M | 255.44M | 337.76M | 403.38M |
| Income Before Tax | 104.67B | 69.06B | 59.08B | 53.13B | 48.55B | 47.62B | 48.68B | 47.80B | 43.48B | 34.10B | 32.54B | 27.81B | 21.93B | 18.29B | 13.99B | 12.73B | 10.98B | 9.17B | 8.22B | 7.51B | 7.58B | 6.29B | 6.01B | 4.84B | 3.96B | 3.75B | 3.17B | 2.53B | 2.15B | 1.93B | 1.87B | 1.67B | 1.46B | 1.14B | 1.05B | 905.31M | 697.44M | 788.58M | 876.68M |
| Income Before Tax Ratio | 45.07% | 39.03% | 41.96% | 41.85% | 39.79% | 42.58% | 43.58% | 42.76% | 40.29% | 38.39% | 38.94% | 35.64% | 33.05% | 30.09% | 27.39% | 27.87% | 26.22% | 23.65% | 24.38% | 25.68% | 28.48% | 25.01% | 25.36% | 23.28% | 18.88% | 20.91% | 18.67% | 16.97% | 15.71% | 14.29% | 14.24% | 15.68% | 14.88% | 13.66% | 13.77% | 16.08% | 13.87% | 18.83% | 21.08% |
| Income Tax Expense | 20.99B | 13.54B | 11.32B | 10.99B | 9.60B | 8.99B | 10.55B | 9.87B | 8.62B | 7.62B | 7.36B | 6.38B | 4.83B | 3.88B | 3.22B | 3.06B | 2.45B | 2.71B | 2.36B | 2.46B | 2.53B | 2.20B | 2.16B | 1.76B | 1.55B | 1.34B | 952.42M | 726.73M | 592.44M | 499.85M | 441.68M | 400.19M | 532.22M | 377.75M | 303.28M | 267.40M | 217.04M | 267.27M | 268.92M |
| Net Income | 83.68B | 55.53B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.93B | 34.86B | 26.48B | 25.18B | 21.43B | 17.10B | 14.40B | 10.77B | 9.67B | 8.54B | 6.45B | 5.86B | 5.05B | 4.87B | 4.09B | 3.85B | 3.09B | 2.41B | 2.41B | 2.22B | 1.80B | 1.56B | 1.43B | 1.43B | 1.27B | 930.19M | 760.12M | 745.99M | 637.91M | 480.40M | 521.32M | 607.76M |
| Net Income Ratio | 36.03% | 31.38% | 33.92% | 33.19% | 31.92% | 34.54% | 34.14% | 33.93% | 32.30% | 29.82% | 30.13% | 27.47% | 25.77% | 23.70% | 21.08% | 21.17% | 20.38% | 16.65% | 17.37% | 17.27% | 18.31% | 16.26% | 16.24% | 14.84% | 11.51% | 13.45% | 13.07% | 12.09% | 11.39% | 10.59% | 10.88% | 11.93% | 9.46% | 9.12% | 9.79% | 11.33% | 9.55% | 12.45% | 14.62% |
| EPS | 9.34 | 12.26 | 10.40 | 9.03 | 4.10 | 3.99 | 7.71 | 7.50 | 6.78 | 5.05 | 4.70 | 7.82 | 3.03 | 2.48 | 1.80 | 1.57 | 1.36 | 1.01 | 0.89 | 0.75 | 0.72 | 0.59 | 0.56 | 0.45 | 0.35 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| EPS Diluted | 9.31 | 12.22 | 10.37 | 9.01 | 4.10 | 3.99 | 7.70 | 7.48 | 6.76 | 5.04 | 4.68 | 7.77 | 3.00 | 2.46 | 1.78 | 1.55 | 1.35 | 1.00 | 0.89 | 0.75 | 0.71 | 0.59 | 0.56 | 0.45 | 0.34 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| Weighted Avg Shares Out | 4.48B | 4.53B | 4.59B | 4.67B | 4.75B | 4.84B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.65B | 5.81B | 5.99B | 3.09B | 3.15B | 3.21B | 3.28B | 3.38B | 3.42B | 3.46B | 3.44B | 3.46B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
| Weighted Avg Shares Out (Dil) | 4.49B | 4.54B | 4.61B | 4.68B | 4.76B | 4.85B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.70B | 5.85B | 6.04B | 3.11B | 3.18B | 3.23B | 3.29B | 3.39B | 3.44B | 3.49B | 3.47B | 3.47B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals
Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's dominance in the weight-loss drug sector. Novo's $16.5 billion acquisition of Catalent aims...
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated...
Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year. Management expects CagriSema to generate 25% weight loss after 68 weeks of treatment. Based on the mechanism of...
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.
Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
Franklin International Equity Fund Q3 2024 Commentary
Jinda Noipho Performance Data Average Annual Total Returns 4(%) 1 Mth 3 Mths 1 Year 3 Year 5 Year 10 Year Since Inception Inception Date Class C (MUTF:LMGEX) - With Sales Charges a -1.46 4.15 21.61 5.98 7.49 4.70 4.22...
Ypsomed will make injection pens for Novo Nordisk's CagriSema, says source
Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source familiar with the matter has told Reuters.
PFE vs. NVO: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
Are Dietary Drug Stocks Eli Lilly and Novo Nordisk Ready To Rise Again?
In today's article I will try to answer the question on whether the two premier diet drug companies stocks have finally stopped going down? I will look at two stocks (dietary drug is in parenthesis): Novo Nordisk NYSE:NVO (Wegovy) and...
Source: https://incomestatements.info
Category: Stock Reports